Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
Business Wire India – The EMPEROR-Preserved Phase III trial met its primary endpoint and demonstrated significant risk reduction with empagliflozin for the composite of cardiovascular death or hospitalization for heart…